Thank you for subscribing!
cannabis stocks
Finfeed Archived Jun 04, 2021
The expansion of its comprehensive distribution agreement with leading nutritional supplements company Route2 Pharm Pvt Ltd, will allow for distribution of Creso Pharma Limited's (ASX: CPH, FRA: 1X8) hemp derived therapeutic products sold under the cannaQIX® and CannaDOL brands into Ecuador.
Finfeed Archived Apr 30, 2021
There were several highlights to come out of the quarterly report released by Creso Pharma (ASX: CPH) today. CPH is enjoying a sustained run this year with revenues up 237% in the lead up to its US listing, which is expected to occur in the coming weeks.
Finfeed Archived Apr 09, 2021
The market continues its up and down ride, just have a look at what Dale Gillham says about it below, however there were a few small cap stocks that delivered decent news this week and saw the benefits.
Finfeed Archived Apr 06, 2021
Creso Pharma (ASX: CPH) has appointed a US Director of Business Development just as New York State has legalised recreational cannabis. New York State is expected to become one of the largest recreational markets in the US valued at US$4.2BN.
Get expert stock analysis direct in your inbox
Finfeed Archived Mar 31, 2021
Creso Pharma’s (ASX: CPH) pending acquisition of Halucenex Life Sciences should prove to be an astute move, with Halucenex continuing to rapidly move towards its goal of developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets.
Finfeed Archived Mar 23, 2021
Creso Pharma (ASX: CPH) today announced it is listing on the OTC market in the USA. Listing on the OTC is expected to unlock significant shareholder value and provides CPH with access to one of the largest investment markets in the world at nominal cost.
Next Investors Jan 19, 2021
Today Creso Pharma (ASX: CPH) reported new and follow up Purchase Orders for its animal health medicinal cannabis products totalling over A$345,000.
Finfeed Archived Jan 08, 2021
Following significant share price movement in response to developments in the US, CPH closed at a high of 26.5c, representing a gain of 44% in a mere 24 hours.
Finfeed Archived Dec 21, 2020
Neurotech International Ltd (ASX: NTI) has today confirmed the successful completion of in-vitro studies using human brain cells to assess and validate the anti-inflammatory and neuro-modulatory properties of its proprietary DOLCE/NTI cannabis leads.
Join Our Mailing List
